Shopping Cart 0
Cart Subtotal
USD 0

Imugene Ltd (IMU) - Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 125

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 250

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 375

Details

Imugene Ltd (IMU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which focuses on the development of vaccines in the area of immune-oncology.The company develops immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene's lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. The company has pipeline products in different phases of clinical trials. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd Key Recent Developments

Jul 26,2019: Imugene: Quarterly activities and cash flow report quarter ended 30 June 2019

May 20,2019: Global Biotechnology and Venture Capital executive joins Imugene Board

Apr 23,2019: Imugene names Dr. Lesley Russell as a Non-Executive Director

Apr 16,2019: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2019

Jan 30,2019: Imugene: Business update-Appendix 4C for the quarter ended 31 December 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Imugene Ltd-Key Facts

Imugene Ltd-Key Employees

Imugene Ltd-Key Employee Biographies

Imugene Ltd-Major Products and Services

Imugene Ltd-History

Imugene Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Imugene Ltd-Business Description

Imugene Ltd-SWOT Analysis

SWOT Analysis-Overview

Imugene Ltd-Strengths

Imugene Ltd-Weaknesses

Imugene Ltd-Opportunities

Imugene Ltd-Threats

Imugene Ltd-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Imugene Ltd, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 26, 2019: Imugene: Quarterly activities and cash flow report quarter ended 30 June 2019

May 20, 2019: Global Biotechnology and Venture Capital executive joins Imugene Board

Apr 23, 2019: Imugene names Dr. Lesley Russell as a Non-Executive Director

Apr 16, 2019: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2019

Jan 30, 2019: Imugene: Business update-Appendix 4C for the quarter ended 31 December 2018

Jan 07, 2019: Imugene names Dr Michael Caligiuri to scientific advisory board

Nov 09, 2018: Imugene receives USD 1. 85 million R&D tax incentive

Oct 30, 2018: Imugene: Business update-Appendix 4C for the quarter ended

Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board

Oct 01, 2018: Imugene names Professor Pravin Kaumaya to Scientific Advisory Board

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Imugene Ltd, Performance Chart (2015-2019)

Imugene Ltd, Ratio Charts

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Imugene Ltd, Key Facts

Imugene Ltd, Key Employees

Imugene Ltd, Key Employee Biographies

Imugene Ltd, Major Products and Services

Imugene Ltd, History

Imugene Ltd, Subsidiaries

Imugene Ltd, Key Competitors

Imugene Ltd, Annual Ratios

Imugene Ltd, Annual Ratios (Cont...1)

Imugene Ltd, Interim Ratios

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Imugene Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Imugene Ltd,SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Rhinomed Limited

Prescient Therapeutics Ltd

Kazia Therapeutics Ltd

Antisense Therapeutics Ltd

Alterity Therapeutics Ltd

Alchemia Ltd

Company Profile

Company Profile Title

Imugene Ltd (IMU)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Imugene Ltd (Imugene) is a clinical stage biopharmaceutical company which focuses on the development of vaccines in the area of immune-oncology.The company develops immunotherapies for the treatment of HER-2+ gastric and breast cancer. The HER-2 receptor works on surface of various tumors including gastric, breast, ovarian and pancreatic cancers. Imugene's lead product candidate, HER-Vaxx is a HER-2+ cancer immunotherapy in Phase II clinical trials for the treatment of gastric cancer and completed Phase I clinical trials for the treatment of breast cancer. It develops vaccine candidates based on Mimotope technology, which uses peptide mimics of conformational epitopes recognized by an antibody with antitumor activity. The company has pipeline products in different phases of clinical trials. Imugene is headquartered in Melbourne, Victoria, Australia.

Imugene Ltd Key Recent Developments

Jul 26,2019: Imugene: Quarterly activities and cash flow report quarter ended 30 June 2019

May 20,2019: Global Biotechnology and Venture Capital executive joins Imugene Board

Apr 23,2019: Imugene names Dr. Lesley Russell as a Non-Executive Director

Apr 16,2019: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2019

Jan 30,2019: Imugene: Business update-Appendix 4C for the quarter ended 31 December 2018

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Section 1-About the Company

Imugene Ltd-Key Facts

Imugene Ltd-Key Employees

Imugene Ltd-Key Employee Biographies

Imugene Ltd-Major Products and Services

Imugene Ltd-History

Imugene Ltd-Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Section 2-Company Analysis

Company Overview

Imugene Ltd-Business Description

Imugene Ltd-SWOT Analysis

SWOT Analysis-Overview

Imugene Ltd-Strengths

Imugene Ltd-Weaknesses

Imugene Ltd-Opportunities

Imugene Ltd-Threats

Imugene Ltd-Key Competitors

Section 3-Company Financial Ratios

Financial Ratios-Annual Ratios

Performance Chart

Financial Performance

Financial Ratios-Interim Ratios

Financial Ratios-Ratio Charts

Section 4-Company's Lifesciences Financial Deals and Alliances

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Imugene Ltd, Recent Deals Summary

Section 5-Company's Recent Developments

Jul 26, 2019: Imugene: Quarterly activities and cash flow report quarter ended 30 June 2019

May 20, 2019: Global Biotechnology and Venture Capital executive joins Imugene Board

Apr 23, 2019: Imugene names Dr. Lesley Russell as a Non-Executive Director

Apr 16, 2019: Imugene: Quarterly activities and cash flow report quarter ended 31 March 2019

Jan 30, 2019: Imugene: Business update-Appendix 4C for the quarter ended 31 December 2018

Jan 07, 2019: Imugene names Dr Michael Caligiuri to scientific advisory board

Nov 09, 2018: Imugene receives USD 1. 85 million R&D tax incentive

Oct 30, 2018: Imugene: Business update-Appendix 4C for the quarter ended

Oct 04, 2018: European Society for Medical Oncology President joins Imugene Scientific Advisory Board

Oct 01, 2018: Imugene names Professor Pravin Kaumaya to Scientific Advisory Board

Section 6-Appendix

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer


List Of Figure

List of Figures

Imugene Ltd, Performance Chart (2015-2019)

Imugene Ltd, Ratio Charts

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019


List Of Table

List of Tables

Imugene Ltd, Key Facts

Imugene Ltd, Key Employees

Imugene Ltd, Key Employee Biographies

Imugene Ltd, Major Products and Services

Imugene Ltd, History

Imugene Ltd, Subsidiaries

Imugene Ltd, Key Competitors

Imugene Ltd, Annual Ratios

Imugene Ltd, Annual Ratios (Cont...1)

Imugene Ltd, Interim Ratios

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

Imugene Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

Imugene Ltd, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Imugene Ltd,SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Rhinomed Limited

Prescient Therapeutics Ltd

Kazia Therapeutics Ltd

Antisense Therapeutics Ltd

Alterity Therapeutics Ltd

Alchemia Ltd